Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of July 2025. The filing details a share repurchase executed on July 2, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital allocation via share buybacks and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased: 479,429 ordinary shares of 31½ pence each.
- Transaction Date: July 2, 2025.
- Price Range: Lowest price paid was 1,403.00p; highest price paid was 1,414.50p.
- Volume-Weighted Average Price (VWAP): 1,408.80p.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Treasury Shares Held: Following this purchase, the Company holds 227,136,326 ordinary shares in treasury.
- Shares in Issue: 4,088,233,873 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.56% of total voting rights.
Material Changes and Program Progress
Since the commencement of the current buyback agreement on June 4, 2025, the Company has purchased an aggregate of 9,001,943 ordinary shares. The July 2 transaction represents a continuation of this existing program. No other material changes to the Company's financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new guidance, outlook, or management commentary regarding future financial performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025.
Investor Verification Checklist
- Verify the total number of treasury shares held (227,136,326) against the latest Form 20-F or quarterly reports to confirm the 5.56% voting rights calculation.
- Confirm the remaining authorization under the buyback program announced on June 4, 2025, to assess future capital return capacity.
- Review the referenced 2024 Form 20-F and 2025 Q1 Results for the specific risk factors mentioned in the cautionary statement.
- Note that this filing does not contain operational financial data (revenue, earnings, cash flow); refer to periodic reports for those metrics.